 There are very limited data describing patient cost in Non-Interventional Studies (NIS) based on a prospective longitudinal patient follow-up design.
 In addition to study outcome concerns arising from patients lost to follow-up (LFU) in pharmacoepidemiology and pharmacovigilance studies, the financial impact of LFU can be significant.
 The objectives of the present analysis were: 1. To determine the cost per patient in prospective longitudinal NIS and to identify variables that may affect this patient cost; 2. To determine theoretical cost of patients lost to follow-up (LFU) and financial benefits that can be expected from LFU minimization through Direct to Patient Contact service (DPC).
 Out of 96 proposals and budgets submitted in 2013, 20 met all the above inclusion criteria. Sponsor geographic origin was well balanced (11 European, 9 US), and most of the studies were international (10 global, 7 regional, 3 single country). See Table 1 for more details.
Return on investment plays an important role for sponsors to determine if DPC strategies are valuable in a study. The financial investment may be beneficial regardless of the cost to ensure completion of the patients, thus meeting the scientific study objectives. And ultimately could generate cost savings as well. 237,500 1,247,500 4,990,000 6,237,500 1,247,500 4,990,000  Annual cost per patient -ranging from €1,068 to €4,370 -decreases as the study duration increases (set-up cost is more diluted in the patient's annual cost). See Figure 1 . The exception being the increased annual patient cost for study duration > 10 years, but it has to be considered as an artifact as explained below in Figures 2 and 3 (see data from rare diseases). But the longer the study, the more expensive the overall cost per patient. See Table 2 .
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 Mean annual patient cost significantly differs according to rarity of disease/population; rarity is an important criterion that greatly impacts overall and annual patient cost, especially for a study lasting more than one year. Below a year, the cost per patient remains quite similar between types of diseases/populations. See Figures 2 and 3 and Table 2 . Table 2 , additional theoretical tables were developed to provide guidance on cost saving amounts if DPC service is included in the study budget, or not, according to three variables and associated modalities: Table 2 . Mean annual cost per patient vs. mean overall cost per patient according to mean study duration Table 3 . Cost saving amounts for all diseases and rare diseases for a sample size of 500 patients *For all diseases, patient costs and saving amounts are not representative for studies > 10 years as they only include rare diseases/populations study proposals.
-The expected patient LFU rate without DPC service, as based on sponsor's indication or Mapi's experience of the disease/population  modalities included LFU rates of 10% -20% -30% -40% and 50%
-The expected patient LFU rate with DPC service, as based on DPC service metrics gathered over the last 13 years and more than 50 studies  modalities included LFU rates of 5% -10%
-The expected patient sample size  modalities included 100; 500; 1,000; and 5,000 patients.
-The calculation to obtain the theoretical cost of LFU is:
Mean overall cost per patient x Expected sample size x Expected LFU rate -The interpretation is: if the cost-saving amount is higher than an X estimated budget developed for a complete DPC service (which includes costs for the setup, patient contact service management, and monthly coordination), it is financially worthwhile to add DPC service in the study design.
 Table 3 is an extract from the theoretical tables that provides cost saving amounts for all diseases (N = 20 proposals), and rare diseases (n= 8 proposals) for an expected sample size of 500 patients; these amounts are quite substantial, especially in rare diseases. 
